NCT01519531View on ClinicalTrials.gov

Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Drug Safety
Interventions
DRUG

Placebo

Oral, daily-dosing for 14 days; matching number of placebo capsule(s) with active arm

DRUG

VIA-3196

Oral, daily dosing for 14 days

Trial Locations (1)

58104

PRACS Institute (formerly Cetero Research), Fargo

Sponsors
All Listed Sponsors
lead

Madrigal Pharmaceuticals, Inc.

INDUSTRY

NCT01519531 - Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects | Biotech Hunter | Biotech Hunter